• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Cipher announces U.S. distribution and supply agreement with Ranbaxy for CIP-ISOTRETINOIN

Mississauga, Ontario - Cipher Pharmaceuticals announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Limited for Ranbaxy to market, sell and distribute CIP-ISOTRETINOIN in the United States, MarketWatch reports.

Mississauga, Ontario

- Cipher Pharmaceuticals announces it has entered into a distribution and supply agreement with Ranbaxy Laboratories Limited for Ranbaxy to market, sell and distribute CIP-ISOTRETINOIN in the United States, MarketWatch reports.

Under the terms of agreement, Cipher received an initial upfront milestone payment of $1 million. Pre-and post- commercialization milestone payments of up to $23 million are also part of the agreement.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.